This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering



NEX-I is a pioneering team in the realm of immuno-oncology, taking innovative footsteps to challenge and transform current cancer treatment methods. At the heart of its cutting-edge strategy is ONCOKINE screening technology, an unprecedented target discovery program developed to overcome the inherent resistance of cancer cells to existing therapies. NEX-I is reshaping the landscape of cancer treatment by spearheading innovative solutions in the persistent battle against cancer.